News

January 10, 2017

Experimental Compound Has Great Potential to Prevent Melanoma Metastases

News

Researchers have identified a compound that could prevent malignant melanoma cells from spreading throughout the body. If the compound is successfully developed into a human drug, it has the potential ... Read more

January 3, 2017

X Chromosome Study Explores Why Melanoma is More Deadly for Men

News

Men who develop melanoma are twice as likely to die from the disease as women, but the molecular mechanisms involved in such disparity remain largely unknown. Now, researchers have pinpointed ... Read more

December 22, 2016

Partners Should Be Trained to Check for Mole Irregularities

News

A new study from Northwestern Medicine shows the advantages of partners frequently checking for potentially dangerous moles, after receiving training to do so. The study, “Self-confidence and Embarrassment About Partner-Assisted Skin ... Read more

December 20, 2016

Treatment Blocking Melanoma Metastasis May Be on the Horizon

News

A treatment preventing cancer metastases may become a reality within a decade, as researchers pinpointed a molecule driving metastasis formation in several cancers, including malignant melanoma. But the findings also ... Read more

December 15, 2016

P15 Protein Levels Could Help Doctors Distinguish Melanoma from Benign Moles

News

Researchers have found that a protein, called p15, may be used as a biomarker to distinguish melanoma from nevi (non-cancerous moles in the skin). Loss of this protein, which inhibits nevus ... Read more

December 13, 2016December 13, 2016

Researchers Link Alcohol Consumption to Risk of Developing Invasive Melanoma

News

Alcohol consumption is associated with a moderate increase in the risk of developing melanoma, according to the findings of a recent study published in the Cancer Epidemiology, Biomarkers & Prevention, a ... Read more

December 2, 2016

Melanoma’s Signature, Disease Development Controlled by CPEB4 Protein, Study Finds

News

Researchers have identified a protein called CPEB4 that seems to be crucial in establishing melanoma’s intrinsic signature and in driving the development of these aggressive tumors. The study, “Lineage-specific roles ... Read more

November 29, 2016November 29, 2016

Virtual Clinical Trial Model Seen to Predict Real Responses of Melanoma Patients to Therapies

News

Researchers with Moffitt Cancer Center developed a computational framework that, they say, can accurately predict patient responses  to cancer treatments in a virtual clinical trial, called phase i. This new methodology integrates actual patient ... Read more

November 17, 2016November 19, 2016

Risk Factors for Melanoma May Influence When and Where Disease Strikes

News

A person’s risk factors for melanoma could be used to tailor surveillance programs and skin self-examinations for those at particular risk, according to a recent study published in JAMA Dermatology. The study, “Clinical Features ... Read more

November 15, 2016November 19, 2016

Diverse Gut Flora Associated with Better Immunotherapy Responses in Melanoma Patients

News

A new research study has found that malignant melanoma patients responded better to immunotherapy treatment when they had more diverse gut flora – microbes and bacteria that live in our ... Read more

November 10, 2016November 10, 2016

Therapy Combination Looks Promising to Treat BRAF-mutant Melanoma Patients

News

Combining the investigational drugs encorafenib and binimetinib to treat advanced melanoma patients provides better progression-free survival and overall response rates than Zelboraf (vemurafenib) monotherapy, according to recent data. The information was presented ... Read more

November 8, 2016November 10, 2016

Immunotherapy Seen as Optimal First-Line Treatment for Advanced Melanoma

News

Patients diagnosed in the late stages of melanoma who have BRAF mutations should be given immunotherapy as a first-line treatment, according to a systematic review published in JAMA Oncology. The study, “Systemic ... Read more

November 6, 2016December 6, 2016

Immunotherapies Should Be First-Line Treatment of High-risk Melanomas, Study Says

News

Patients with advanced melanoma have improved survival rates with superior safety when treated with protocols that combine immunotherapy options, researchers recommended. The study, “Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: ... Read more

November 3, 2016

Specialized Melanoma Surveillance Provides Better Outcomes, Lower Costs than Standard of Care, Study Finds

News

Clinical guidelines recommend that people at high risk for melanoma receive regular surveillance to improve survival through early cancer detection. In a recent Australian study, researchers have shown that monitoring ... Read more

November 1, 2016November 1, 2016

Promising Clinical Data from Melanoma Combination Therapy to Be Presented at Upcoming Meeting

News

Array BioPharma and Pierre Fabre will present data from the COLUMBUS Phase 3 clinical trial showing that melanoma patients with BRAF mutations may benefit more from the combination of encorafenib and ... Read more

October 27, 2016

Nearly One-Third of Metastatic Melanoma Patients in Europe Can’t Access Best Therapies for Survival, Survey Shows

News

Despite the advances in innovative targeted therapies and immunotherapies that largely increase melanoma survival rates, nearly one-third of metastatic melanoma patients in Europe are denied access to those new medicines. ... Read more

October 25, 2016October 25, 2016

Success of Melanoma Immunotherapy Boosted by Cells Grown in Antioxidant, Study Finds

News

Adoptive cell transfer — a type of immunotherapy when a patient’s own T-cells are harvested, genetically modified, and expanded in the lab — is much more efficient in melanoma if researchers make a ... Read more

October 20, 2016May 29, 2017

Keytruda and Yervoy Combo Shows Strong Activity in Advanced Melanoma Study

News

Combining two immunotherapies that block distinct immune checkpoints may be a promising approach for patients with advanced melanoma. According to data from a Phase 1/2 study, the Keytruda (pembrolizumab) plus Yervoy (ipilimumab) combination ... Read more

October 18, 2016October 18, 2016

New Psychological Intervention Eases Fears of Melanoma Recurrence

News

A new psychological intervention developed by a team of researchers based at Australia’s University of New South Wales, The University of Sydney, and the Melanoma Institute Australia, in partnership with ... Read more

October 13, 2016

Combo Therapy for Advanced Melanoma, Tafinlar and Mekinist, Seen to Improve 3-Year Survival

News

Combination treatment with Novartis‘ Tafinlar (dabrafenib) and Mekinist (trametinib) improved survival of advanced myeloma patients at three years, compared to patients treated with a BRAF blocker. These findings emerged as ... Read more